Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.43 |
| ▸ | TACR2 | P21452 | 4/20 | 0.38 |
| ▸ | TACR1 | P25103 | 4/20 | 0.38 |
| ▸ | TACR3 | P29371 | 4/20 | 0.38 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009094 | 0.94 | GRM5 (0.43) | GRM5TACR2TACR1TACR3ALDH1A1 | |
| SCHEMBL1009399 | 0.90 | GRM5 (0.48) | GRM5ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1009927 | 0.87 | GRM5 (0.43) | GRM5TACR3QRFPRALDH1A1LMNA | |
| SCHEMBL3816728 | 0.86 | TACR3 (0.41) | TACR2TACR1TACR3QRFPRLMNA | |
| SCHEMBL1012947 | 0.85 | GRM5 (0.42) | GRM5TACR2TACR1TACR3ALDH1A1 | |
| SCHEMBL1011369 | 0.85 | GRM5 (0.49) | GRM5ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1010322 | 0.84 | GRM5 (0.43) | GRM5QRFPRALDH1A1LMNAHPGD | |
| SCHEMBL1010814 | 0.84 | GRM5 (0.42) | GRM5TACR2TACR1TACR3ALDH1A1 | |
| SCHEMBL1011553 | 0.84 | GRM5 (0.42) | GRM5QRFPRALDH1A1LMNAHPGD | |
| SCHEMBL1013048 | 0.84 | GRM5 (0.43) | GRM5QRFPRALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | disclosed |
| EP-2295439-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2011-03-16 | — | — | EP | disclosed |
| EP-2054416-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2011-01-05 | — | — | EP | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | GRM5 1/4885TACR2 536/4885TACR1 428/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | GRM5 1/4885TACR2 740/4885TACR1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.